Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma.

Kubota K, Hidaka H, Nakazawa T, Okuwaki Y, Yamane K, Inoue T, Uojima H, Takada J, Tanaka Y, Shibuya A, Fujii K, Woodhams R, Matsunaga K, Kokubu S, Koizumi W.

Hepatol Res. 2018 Feb;48(3):E98-E106. doi: 10.1111/hepr.12933. Epub 2017 Jul 30.

PMID:
28656607
2.

Superparamagnetic iron oxide-enhanced magnetic resonance imaging is useful in predicting malignant potential of vascular transformation of hypointense hypovascular nodules on gadoxetic acid-enhanced magnetic resonance imaging.

Tanaka Y, Nakazawa T, Inoue T, Yamane K, Kubota K, Uojima H, Takada J, Okuwaki Y, Hidaka H, Shibuya A, Kokubu S, Matsunaga K, Koizumi W.

Hepatol Res. 2017 Oct;47(11):1118-1126. doi: 10.1111/hepr.12850. Epub 2017 Feb 21.

PMID:
27943555
3.

Three-dimensional computed tomography of portopulmonary venous anastomoses in patients with esophageal varices before treatment.

Matsumoto Y, Hidaka H, Matsunaga K, Kubota K, Yamane K, Inoue T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Nakazawa T, Shibuya A, Koizumi W.

Hepatol Res. 2016 May;46(6):559-64. doi: 10.1111/hepr.12591. Epub 2015 Oct 8.

PMID:
26355776
4.

Early evaluation of response to sorafenib for hepatocellular carcinoma by duplex Doppler ultrasonography.

Hidaka H, Nakazawa T, Fujii S, Yanagihara M, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Shibuya A, Koizumi W.

Hepatol Res. 2015 Sep;45(9):976-985. doi: 10.1111/hepr.12440. Epub 2014 Dec 11.

PMID:
25336196
5.

Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.

Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, Minamino T, Watanabe M, Kokubu S, Koizumi W.

BMC Gastroenterol. 2014 May 3;14:84. doi: 10.1186/1471-230X-14-84.

6.

Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis.

Morimoto M, Numata K, Kondo M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Okuwaki Y, Okuse C, Matsunaga K, Suzuki M, Morita S, Taguri M, Tanaka K.

Hepatol Res. 2015 Mar;45(3):279-87. doi: 10.1111/hepr.12354. Epub 2014 May 28.

PMID:
24802232
7.

Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes.

Tanaka Y, Nakazawa T, Komori S, Hidaka H, Okuwaki Y, Takada J, Watanabe M, Shibuya A, Minamino T, Yamamoto H, Kokubu S, Hayakawa K, Koizumi W.

J Gastroenterol Hepatol. 2014 Feb;29(2):352-7. doi: 10.1111/jgh.12333.

PMID:
23869689
8.

Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.

Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, Shibuya A, Minamino T, Kokubu S, Koizumi W.

Eur J Gastroenterol Hepatol. 2013 Jun;25(6):683-9. doi: 10.1097/MEG.0b013e32835d913b.

PMID:
23395995
9.

The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis.

Hidaka H, Nakazawa T, Kutsukake S, Yamazaki Y, Aoki I, Nakano S, Asaba N, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Koizumi W.

J Gastroenterol. 2013 Feb;48(2):269-76. doi: 10.1007/s00535-012-0632-x. Epub 2012 Jul 24.

PMID:
22825550
10.

[Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].

Kobayashi S, Ohkawa S, Kondo M, Morimoto M, Numata K, Matsunaga K, Okuse C, Suzuki M, Hidaka H, Takada J, Okuwaki Y, Shibuya A, Tanaka K.

Gan To Kagaku Ryoho. 2012 Jul;39(7):1065-70. Japanese.

PMID:
22790040
11.

Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study.

Hidaka H, Nakazawa T, Kaneko T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Koizumi W.

J Gastroenterol. 2012 Sep;47(9):1030-5. doi: 10.1007/s00535-012-0563-6. Epub 2012 Mar 9.

PMID:
22402773
12.

Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report.

Okuwaki Y, Nakazawa T, Hidaka H, Shibuya A, Koizumi W.

J Med Case Rep. 2012 Jan 26;6:38. doi: 10.1186/1752-1947-6-38.

13.

Branch retinal artery occlusion and central retinal vein occlusion associated with pegylated interferon plus ribavirin combination therapy for chronic hepatitis C.

Watanabe M, Ogasawara S, Takahashi A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Shibuya A, Koizumi W.

Cutan Ocul Toxicol. 2012 Sep;31(3):253-7. doi: 10.3109/15569527.2011.641197. Epub 2011 Dec 16.

PMID:
22172047
14.

Long-term administration of PPI reduces treatment failures after esophageal variceal band ligation: a randomized, controlled trial.

Hidaka H, Nakazawa T, Wang G, Kokubu S, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Tanabe S, Shibuya A, Koizumi W.

J Gastroenterol. 2012 Feb;47(2):118-26. doi: 10.1007/s00535-011-0472-0. Epub 2011 Sep 28.

PMID:
21947706
15.

Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial.

Hidaka H, Nakazawa T, Shibuya A, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Koizumi W.

J Gastroenterol. 2011 Nov;46(11):1316-23. doi: 10.1007/s00535-011-0449-z. Epub 2011 Aug 18.

PMID:
21850387
16.

Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels.

Nakazawa T, Shibuya A, Takeuchi A, Shibata Y, Hidaka H, Okuwaki Y, Takada J, Tanaka Y, Watanabe M, Minamino T, Sakurai K, Koizumi W.

J Viral Hepat. 2011 Jul;18(7):e191-9. doi: 10.1111/j.1365-2893.2010.01427.x. Epub 2011 Jan 11.

PMID:
21692932
17.

Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection.

Watanabe M, Shibuya A, Tsunoda Y, Danbara M, Ishii R, Ohsaka M, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Horie R, Higashihara M, Koizumi W.

Liver Int. 2011 Mar;31(3):340-7. doi: 10.1111/j.1478-3231.2010.02417.x. Epub 2010 Dec 7.

PMID:
21134110
18.

Reliability and validity of splenic volume measurement by 3-D ultrasound.

Hidaka H, Nakazawa T, Wang G, Kokubu S, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Koizumi W.

Hepatol Res. 2010 Oct;40(10):979-88. doi: 10.1111/j.1872-034X.2010.00705.x.

PMID:
20887333
19.

Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.

Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Koizumi W.

Eur J Intern Med. 2010 Aug;21(4):333-7. doi: 10.1016/j.ejim.2010.04.010. Epub 2010 May 26.

PMID:
20603047
20.

Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma.

Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J, Watanabe M, Shibuya A, Minamino T, Saigenji K.

Am J Gastroenterol. 2009 Nov;104(11):2747-53. doi: 10.1038/ajg.2009.414. Epub 2009 Jul 14.

PMID:
19603009
21.

Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation.

Hidaka H, Kokubu S, Nakazawa T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K.

Hepatol Res. 2009 Aug;39(8):772-8. doi: 10.1111/j.1872-034X.2009.00508.x. Epub 2009 Mar 25.

PMID:
19473438
22.

Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.

Nakazawa T, Adachi S, Kitano M, Isobe Y, Kokubu S, Hidaka H, Ono K, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K.

Oncology. 2007;73(1-2):90-7. doi: 10.1159/000120996. Epub 2008 Mar 13.

PMID:
18337620
23.

Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns.

Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K.

J Gastroenterol. 2008;43(1):71-8. doi: 10.1007/s00535-007-2123-z. Epub 2008 Feb 24.

PMID:
18297439
24.

Longitudinal epidemiology of Chlamydia trachomatis serovars in female patients in Japan.

Takahashi S, Yamazaki T, Satoh K, Inoue M, Takahashi S, Ishihara O, Oka Y, Horiguchi Y, Okuwaki Y, Suzuki S, Kishimoto T.

Jpn J Infect Dis. 2007 Nov;60(6):374-6.

25.

L-Ficolin/mannose-binding lectin-associated serine protease complexes bind to group B streptococci primarily through N-acetylneuraminic acid of capsular polysaccharide and activate the complement pathway.

Aoyagi Y, Adderson EE, Rubens CE, Bohnsack JF, Min JG, Matsushita M, Fujita T, Okuwaki Y, Takahashi S.

Infect Immun. 2008 Jan;76(1):179-88. Epub 2007 Oct 15.

26.

New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis.

Hidaka H, Kokubu S, Nakazawa T, Okuwaki Y, Ono K, Watanabe M, Shibuya A, Saigenji K.

Hepatol Res. 2007 Dec;37(12):1011-7. Epub 2007 Jul 1.

PMID:
17608670
27.

Spontaneous rupture of a left gastroepiploic artery aneurysm in a patient with autosomal-dominant polycystic kidney disease.

Nagaba Y, Nishimaki H, Ichinoe M, Okuwaki Y, Hamura M, Makino T, Sano T, Higashihara M, Kamata K, Soma K.

Clin Nephrol. 2005 Feb;63(2):163-6.

PMID:
15730059
28.

Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci.

Aoyagi Y, Adderson EE, Min JG, Matsushita M, Fujita T, Takahashi S, Okuwaki Y, Bohnsack JF.

J Immunol. 2005 Jan 1;174(1):418-25.

29.

Class specific influence of dietary Spirulina platensis on antibody production in mice.

Hayashi O, Hirahashi T, Katoh T, Miyajima H, Hirano T, Okuwaki Y.

J Nutr Sci Vitaminol (Tokyo). 1998 Dec;44(6):841-51.

PMID:
10197315
30.

Capsular sialic acid limits C5a production on type III group B streptococci.

Takahashi S, Aoyagi Y, Adderson EE, Okuwaki Y, Bohnsack JF.

Infect Immun. 1999 Apr;67(4):1866-70.

31.

Role of C5a-ase in group B streptococcal resistance to opsonophagocytic killing.

Takahashi S, Nagano Y, Nagano N, Hayashi O, Taguchi F, Okuwaki Y.

Infect Immun. 1995 Dec;63(12):4764-9.

32.

Enhancement of antibody production in mice by dietary Spirulina platensis.

Hayashi O, Katoh T, Okuwaki Y.

J Nutr Sci Vitaminol (Tokyo). 1994 Oct;40(5):431-41.

PMID:
7891204
33.

Opsonisation of group B streptococci and restriction endonuclease digestion patterns of their chromosomal DNA.

Takahashi S, Nagano Y, Nagano N, Fujita K, Taguchi F, Okuwaki Y.

J Med Microbiol. 1993 Mar;38(3):191-6.

PMID:
8455188
34.

Restriction endonuclease digest patterns of chromosomal DNA from group B beta-haemolytic streptococci.

Nagano Y, Nagano N, Takahashi S, Murono K, Fujita K, Taguchi F, Okuwaki Y.

J Med Microbiol. 1991 Nov;35(5):297-303.

PMID:
1658325
35.
36.
37.

[The influence of low ambient temperature on the immune response of mice (author's transl)].

Okuwaki Y.

Nihon Eiseigaku Zasshi. 1982 Feb;36(6):895-903. Japanese. No abstract available.

PMID:
7087251
38.

[Case of Rotor type hyperbilirubinemia with elevation indirect serum bilirubin].

Hannya K, Uesugi S, Okuwaki Y, Imamoto S, Tanaka Y.

Nihon Ika Daigaku Zasshi. 1969;36(1):96-100. Japanese. No abstract available.

PMID:
5768302

Supplemental Content

Loading ...
Support Center